| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BIRC3 |
| Uniprot No | Q13489 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-604aa |
| 氨基酸序列 | MNIVENSIFL SNLMKSANTF ELKYDLSCEL YRMSTYSTFP AGVPVSERSL ARAGFYYTGV NDKVKCFCCG LMLDNWKRGD SPTEKHKKLY PSCRFVQSLN SVNNLEATSQ PTFPSSVTNS THSLLPGTEN SGYFRGSYSN SPSNPVNSRA NQDFSALMRS SYHCAMNNEN ARLLTFQTWP LTFLSPTDLA KAGFYYIGPG DRVACFACGG KLSNWEPKDN AMSEHLRHFP KCPFIENQLQ DTSRYTVSNL SMQTHAARFK TFFNWPSSVL VNPEQLASAG FYYVGNSDDV KCFCCDGGLR CWESGDDPWV QHAKWFPRCE YLIRIKGQEF IRQVQASYPH LLEQLLSTSD SPGDENAESS IIHFEPGEDH SEDAIMMNTP VINAAVEMGF SRSLVKQTVQ RKILATGENY RLVNDLVLDL LNAEDEIREE ERERATEEKE SNDLLLIRKN RMALFQHLTC VIPILDSLLT AGIINEQEHD VIKQKTQTSL QARELIDTIL VKGNIAATVF RNSLQEAEAV LYEHLFVQQD IKYIPTEDVS DLPVEEQLRR LQEERTCKVC MDKEVSIVFI PCGHLVVCKD CAPSLRKCPI CRSTIKGTVR TFLS |
| 预测分子量 | 68,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BIRC3重组蛋白的3篇文献示例(注：文献为模拟虚构，仅供参考格式)：
1. **"Recombinant BIRC3 protein inhibits caspase activity and enhances cell survival"**
- **作者**: Müller A, et al.
- **摘要**: 研究通过大肠杆菌表达系统制备重组BIRC3蛋白，证实其通过直接结合caspase-9抑制凋亡，并在体外实验中显著提高HeLa细胞的存活率。
2. **"Structural characterization of BIRC3 recombinant protein and its interaction with TRAF2"**
- **作者**: Chen L, et al.
- **摘要**: 利用X射线晶体学解析重组BIRC3蛋白结构，揭示其BIR结构域与TRAF2的结合位点，为靶向NF-κB通路的药物设计提供依据。
3. **"Functional screening of BIRC3 variants using recombinant proteins in inflammatory signaling"**
- **作者**: Rossi F, et al.
- **摘要**: 构建多种BIRC3突变体重组蛋白，发现特定突变体(如p.Cys308Trp)丧失抑制细胞凋亡功能，并导致TLR信号通路异常激活。
(提示：实际文献需通过PubMed/Google Scholar检索，建议结合关键词“BIRC3 recombinant protein”或“BIRC3 expression and function”进一步筛选。)
BIRC3 (Baculoviral IAP Repeat-Containing Protein 3), also known as cIAP2 or API2. is a member of the inhibitor of apoptosis (IAP) family, which plays a critical role in regulating cell survival, apoptosis, and inflammatory signaling. Structurally, it contains three baculoviral IAP repeat (BIR) domains that mediate interactions with caspases (e.g., caspase-3. -7. and -9) to suppress their pro-apoptotic activity, and a RING finger domain conferring E3 ubiquitin ligase activity for modulating protein degradation pathways. BIRC3 is a key component of the NF-κB signaling network, where it stabilizes signaling complexes (e.g., TRAF2) and promotes ubiquitination-dependent activation of pro-survival pathways.
Dysregulation of BIRC3 is implicated in various diseases. In cancer, chromosomal translocations (e.g., API2-MALT1 in MALT lymphoma) or overexpression of BIRC3 contribute to tumor progression and chemoresistance by blocking apoptosis. Conversely, loss-of-function mutations in BIRC3 are linked to immunodeficiency disorders, such as common variable immunodeficiency (CVID), due to impaired NF-κB activation. In inflammatory diseases, BIRC3 modulates immune responses through interactions with NOD2. impacting Crohn’s disease pathogenesis.
Recombinant BIRC3 protein is engineered using expression systems (e.g., E. coli, mammalian cells) for functional studies. It enables researchers to dissect its structural domains, map binding partners (e.g., caspases, TRAFs), and screen therapeutic agents targeting IAP-mediated survival pathways. Applications include exploring BIRC3’s role in cancer resistance, inflammatory signaling, and developing IAP antagonists (e.g., SMAC mimetics) to sensitize malignant cells to apoptosis. Purified recombinant BIRC3 often includes tags (e.g., His, GST) for affinity-based isolation and activity validation via biochemical assays (e.g., ubiquitination, caspase inhibition). Its study provides insights into cell death regulation and opportunities for therapeutic intervention in oncology and immune disorders.
×
